Parkinson's Disease (PD)Phase 1NCT07718659
ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's Disease
A Phase 1 study testing ZR001 in people with Parkinson's Disease (PD) and Parkinsonian Disorders, run by Qianfoshan Hospital at 1 site in China.
Trial summary
This study aims to evaluate the safety, tolerability, and preliminary efficacy of ZR001, a novel chemogenetic gene therapy product, in patients with moderately advanced Parkinson's disease (PD). Read more about this study
- Who is it for?
- Ages 40 to 70 years
- Conditions the study is for
- Parkinson's Disease (PD), Parkinsonian Disorders
- What is being tested?
- ZR001
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 8 participants
- Where
- 1 siteChina
- Study dates
- 1 Dec 2026to 1 Dec 2030
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants who meet all of the following criteria are eligible for enrollment:
- Age ≥40 and ≤70 years (at the time of signing the informed consent), any gender.
- Diagnosed with Parkinson's disease according to the Diagnostic Criteria for Parkinson's Disease in China (2016 edition).
- Modified Hoehn \& Yahr stage between 2.5 and 4.
- History of Parkinson's disease for at least 5 years but less than 15 years.
- Moderate to severe MDS-UPDRS Part III score in the off period, and improvement rate ≥30% after acute levodopa stress test.
Show all 11Show fewer
- Clinically stable symptoms and stable types and doses of anti-Parkinsonian medications within 3 months prior to enrollment.
- Agree to provide biological samples required for the study (e.g., blood, urine).
- Consent to hospitalization for intraparenchymal drug injection surgery.
- Male or female participants of childbearing potential agree to use effective contraceptive methods (oral contraceptives are prohibited) from the time of signing the informed consent until at least 6 months after discontinuing clozapine.
- Participants or their stable caregivers are able to understand and willing to comply with the study requirements and procedures, voluntarily participate, and sign the informed consent. If a caregiver is present, they must accompany the participant to study visits and assist the investigator in completing relevant scale assessments.
Who cannot join
- Participants who meet any of the following criteria will be excluded from this study:
- Have participated in or are currently participating in other clinical studies of PD drugs or other AAV gene therapy or cell therapy.
- Presence of other severe psychiatric disorders (e.g., severe depression, schizophrenia, etc.).
- Previous adverse reactions to clozapine, such as agranulocytosis or severe neutropenia.
- Participants with known allergic constitution, including allergy or hypersensitivity to clozapine, prednisone acetate, other glucocorticoids, their excipients, or local anesthetics.
- History of alcohol or drug abuse within the past 2 years.
Show all 17Show fewer
- Participants requiring invasive or non-invasive ventilatory support.
- Serum AAV binding antibody titer >1:2000.
- Presence of clinically significant laboratory abnormalities as assessed by the investigator: alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), total bilirubin; creatinine, hemoglobin (Hb), prothrombin time (PT), activated partial thromboplastin time (APTT), fasting blood glucose, platelets (PLT).
- Presence of liver disease, heart disease, kidney disease or history thereof, which, in the investigator's assessment, may pose surgical or drug-related risks to the participant.
- Suffering from autoimmune diseases or immunocompromised status requiring hormone or immunosuppressive therapy, which, in the investigator's assessment, may pose surgical or drug-related risks.
- Suffering from other severe systemic diseases (e.g., cor pulmonale, moderate-to-severe asthma, etc.) that, in the investigator's assessment, may pose surgical or drug-related risks.
- In the investigator's assessment, the participant has contraindications to anesthesia or surgery and is unsuitable for intraparenchymal administration, or other special circumstances.
- Positive for human immunodeficiency virus antibody, hepatitis B surface antigen, hepatitis C antibody, syphilis antibody, active TORCH virus infection, or active Epstein-Barr virus infection.
- Concomitant use of any of the following medications within 90 days prior to administration, or planned immunosuppressive therapy (cyclosporine, tacrolimus, methotrexate, cyclophosphamide, intravenous immunoglobulin, rituximab) within 6 months after start of the trial, except for prophylactic medications specified in the protocol.
- Pregnant or breastfeeding women, or those planning to become pregnant.
- Other conditions that, in the investigator's opinion, make the participant unsuitable for participation in this study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
Jinan, Shandong
Peng Zhou, Associate Chief Physician, 086+13954158293, fzsf999@163.com
Tao Xin, Chief Physician & Professor
About this study
Official title: An Open-label, Single Arm, Dose-Escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ZR001, a Gene Therapy Based on Chemogenetics, for the Treatment of Parkinson's Disease
This study aims to evaluate the safety, tolerability, and preliminary efficacy of ZR001, a novel chemogenetic gene therapy product, in patients with moderately advanced Parkinson's disease (PD). ZR001 is administered via stereotactic injection into the bilateral substantia nigra, followed by postoperative ultra-low-dose clozapine to activate the transduced direct pathway, with the goal of improving motor symptoms of Parkinson's disease.
Read the detailed description
This is a first-in-human (FIH), open-label, single-arm, single-dose, dose-escalation study. The trial plans to enroll 6-8 patients with moderately advanced PD across three dose cohorts: 0.5E12, 1.0E12, and 2.0E12 vg/participant. All participants will receive a single bilateral stereotactic injection into the substantia nigra under robot-assisted guidance. To mitigate immunogenicity, prophylactic corticosteroids will be administered (intravenous methylprednisolone followed by a 12-week oral prednisone taper). Four weeks after injection, oral clozapine will be titrated over 9 days to a maintenance dose of 3.125 mg (1/8 tablet) twice daily, continued through Week 52. The study includes a 60-day screening period, an inpatient stay from Day 1 to Day 7, and outpatient follow-up visits through Week 52 at Weeks 4, 8, 12, 26, 39, and 52. After completion, participants will be invited to participate in a 5-year long-term follow-up study.
- Conditions
- Parkinson's Disease (PD), Parkinsonian Disorders
- Being tested
- ZR001
- Keywords
- AAV, DREADD, PD, D1-MSN, Gene Therapy, Chemogenetics, Parkinson's Disease, Clozapine, Central Nervous System Diseases, Movement Disorders, Neurodegenerative Diseases
- Medical subject headings
- Parkinson Disease, Parkinsonian Disorders, Central Nervous System Diseases, Movement Disorders, Neurodegenerative Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ZR001Genetic
This is a prospective, open-label, single-arm, single-dose, dose-escalation, investigator-initiated trial. A sentinel-based 3+ design will evaluate three dose cohorts: 0.5E12, 1.0E12, and 2.0E12 vg/participant. One sentinel participant is enrolled per cohort; a Safety Review Committee assesses safety at 6-8 weeks post-injection before escalation. After completing escalation, remaining participants are enrolled at the selected dose for expansion. Total planned enrollment is 6-8 evaluable participants.
| Study group | Role | What they receive |
|---|---|---|
| ZR001 group | Experimental | The study will enroll up to 3 cohorts: low-dose, medium-dose, and high-dose ZR001 administration. Receives: Genetic: ZR001 |
What is being measured
The primary outcome is the main question the study is designed to answer.
The incidence of adverse events and serious adverse events after ZR001 treatment
Adverse events and serious adverse events will be collected from dosing through Week 52; Including vital signs, clinical laboratory parameters, and physical examinations
Measured: 52 weeks
Secondary outcomes (14)
The differences of the daily levodopa equivalent dose (LED) after ZR001 treatment
Compare total daily LED (collected from dosing through Week 52) with baseline; LED is calculated using standard conversion factors for all dopaminergic medications
Measured: 52 weeks
The differences of the Clinical Global Impression - Severity (CGI-S) after ZR001 treatment
Compare the change in CGI-S scores from baseline to post-treatment; CGI-S is a 7-point-scale (1 = normal to 7 = among the most extremely ill)
Measured: 52 weeks
The differences of the Clinical Global Impression - Improvement (CGI-I) after ZR001 treatment
Compare the change in CGI-I scores from baseline to post-treatment; CGI-I is a 7-point-scale (1 = very much improved to 7 = very much worse)
Measured: 52 weeks
The differences of the MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS) after ZR001 treatment
Change from baseline in the total UPDRS score and subscores for Parts I-IV. The UPDRS is an internationally recognized rating scale for Parkinson's disease symptoms. It comprises 4 parts assessing non-motor and motor experiences of daily living and motor complications. The total score is the sum of all 4 part scores, ranging from 0 to 183 (Part I: 0-16, Part II: 0-52, Part III: 0-56, Part IV: 0-23), with higher scores indicating greater severity of Parkinson's disease symptoms. Part I assesses non-motor experiences of daily living, including neuropsychiatric symptoms such as cognition, mood, and behavior. Part II assesses motor experiences of daily living, including activities such as writing, dressing, personal hygiene, and turning in bed. Part III assesses motor function through clinician-scored examination, including facial expression, tremor, rigidity, bradykinesia, postural instability, and gait. Part IV assesses motor complications, including dyskinesia and motor fluctuations.
Measured: 52 weeks
The differences of the Parkinson's Disease Questionnaire 39 (PDQ-39) after ZR001 treatment
Compare the change from baseline to Week 52 in PDQ-39 score; The PDQ-39 is a 39-item questionnaire, with each item scored from 0 to 4, where 0 = never and 4 = always or unable to do at all. Item scores are summed, higher scores indicating worse quality of life.
Measured: 52 weeks
The differences of the Non-Motor Symptom Scale (NMSS) after ZR001 treatment
Change from baseline in the NMSS total score. The NMSS is a 30-item scale covering 9 dimensions assessing non-motor symptoms in Parkinson's disease. Each item evaluates both severity and frequency of each symptom. Severity is scored from 0 to 3, where 0 = none, 1 = mild (symptom present but causes slight discomfort or distress), 2 = moderate (symptom causes some distress), and 3 = severe (symptom causes great distress). Frequency is scored from 1 to 4, where 1 = rarely (less than once a week), 2 = often (once a week), 3 = frequently (several times a week), and 4 = very frequently (daily or continuously present). For each item, the final score is calculated as severity × frequency (product). The total score is the sum of all 30 item products, ranging from 0 to 360, with higher scores indicating greater severity and higher frequency of non-motor symptoms. Units are expressed as the score on the 0-360 scale. Assessments are performed at specified post-treatment timepoints.
Measured: 52 weeks
The differences of the Parkinson's Disease Sleep Scale (PDSS) after ZR001 treatment
Change from baseline in the PDSS total score. The PDSS is a 15-item scale assessing common sleep disturbances in Parkinson's disease. Each item is scored from 0 to 10, with the total score calculated as the sum of all 15 items, ranging from 0 to 150. Higher scores indicate worse sleep quality.
Measured: 52 weeks
The differences of the Pittsburgh Sleep Quality Index (PSQI) after ZR001 treatment
Change from baseline to Week 52 in PSQI global score; The PSQI is a standardized instrument developed by the Sleep Research Center at the University of Pittsburgh Medical Center for assessing sleep quality. It comprises 7 components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each component is scored, and the total score is ranging from 0 to 21. Higher scores indicate worse sleep quality, with a total score >5 generally considered indicative of poor sleep quality.
Measured: 52 weeks
The differences of the Montreal Cognitive Assessment (MoCA) after ZR001 treatment
Change from baseline to Week 52 in MoCA total score; The MoCA is a neuropsychological assessment tool developed by Nasreddine and colleagues in 2004 at McGill University, Canada. It covers 8 cognitive domains, including attention and concentration, executive functions, memory, language, and visuospatial skills, and comprises 11 testing tasks such as the Trail Making Test (alternating), cube copying, and delayed recall of memory. The total score is ranging from 0 to 30. A score of ≥26 is generally considered as normal, with lower scores indicating cognitive impairment.
Measured: 52 weeks
The differences of the Mini Mental State Examination (MMSE) after ZR001 treatment
Change from baseline in the MMSE total score. The MMSE is a screening tool for cognitive and intellectual function impairment in the elderly, developed by Folstein and colleagues in 1975 in the United States. The scale comprises 5 cognitive domains: orientation, registration(memory), attention and calculation, recall, and language. Each item is scored 1 point for a correct answer, and 0 points for an incorrect answer or unknown. The total score ranges from 0 to 30, with higher scores indicating better cognitive function. The cut-off for dementia is adjusted by educational level: <17 for illiterate individuals, <20 for primary school education, and <24 for middle school education or above are considered indicative of dementia. Severity reference: 27-30 = normal, 21-26 = mild, 10-20 = moderate, and 0-9 = sever
Measured: 52 weeks
The differences of the Hamilton Depression Rating Scale (HAM-D) after ZR001 treatment
Change from baseline in the HAM-D total score. The HAM-D is a clinician-rated scale developed by Hamilton in 1960 for assessing the severity of depressive symptoms and evaluating treatment response. Assessments are performed through interview and observation. The total score is calculated as the sum of all item scores, ranging from 0 to 52, with higher scores indicating greater severity of depression.
Clinical interpretation: total score < 8 = normal; 8-20 = possible depression; 20-35 = definite depression; > 35 = severe depression. A score of ≥ 20 is generally considered to indicate moderate to severe depressive symptoms.
Measured: 52 weeks
The differences of the Hamilton Anxiety Scale (HAM-A) after ZR001 treatment
Change from baseline in the HAM-A total score. The HAM-A can be used to evaluate the severity of anxiety symptoms in patients with anxiety and depressive disorders, as well as to assess treatment response to various pharmacological and psychological interventions. All items are rated on a 5-point scale from 0 to 4, where 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe. The total score is calculated as the sum of all item scores, ranging from 0 to 56, with higher scores indicating greater severity of anxiety. Clinical interpretation: total score < 7 = no anxiety; 7-13 = possible anxiety; 14-20 = definite anxiety; 21-28 = definite marked anxiety; ≥ 29 = severe anxiety. Additionally, scores of ≥ 17, ≥ 25, and ≥ 30 are commonly used as thresholds for mild, moderate, and severe anxiety respectively.
Measured: 52 weeks
The differences of the viral shedding after ZR001 treatment
Detection of vector DNA by qPCR in blood, saliva, urine, and feces at baseline and at Day 7, Weeks 4, 8, 12, 26, 39, and 52 post-dose
Measured: 52 weeks
The humoral and cellular immune responses to ZR001
Change from baseline to Week 52 in humoral and cellular immune responses to ZR001
Measured: 52 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2026
- Study start1 Dec 2026 (estimated)
- Primary completion1 Dec 2029 (estimated)
- Study completion1 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson's Disease (PD)Studies of the same condition, open and under way.
- More trials run by Qianfoshan HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Single Group Assignment: An Open-label, Single Arm, Dose-Escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ZR001 administration.
- Masking
- None (open label)
- Enrolment
- 8 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Qianfoshan Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Shenzhen Loongen Biotechnology Co., Ltd.
- Responsible party
- Principal investigator, Tao Xin, Qianfoshan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07718659
- Sponsor's protocol ID
- ZR001-101
- Other IDs
- YXLL-KY-2026 (101)
- Status last verified
- Jul 2026
- First submitted
- 1 Jul 2026
- Last updated
- 22 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label, Single Arm, Dose-Escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ZR001, a Gene Therapy Based on Chemogenetics, for the Treatment of Parkinson's Disease
- ClinicalTrials.gov ID
- NCT07718659
- Acronym / sponsor ID
- ZR001-101
- Conditions
- Parkinson's Disease (PD), Parkinsonian Disorders
- Keywords
- AAV, DREADD, PD, D1-MSN, Gene Therapy, Chemogenetics, Parkinson's Disease, Clozapine
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 8 participants (estimated)
- Lead sponsor
- Qianfoshan HospitalUniversity, hospital or other
- Collaborators
- Shenzhen Loongen Biotechnology Co., Ltd.
- Study start
- 1 Dec 2026 (estimated)
- Primary completion
- 1 Dec 2029 (estimated)
- Study completion
- 1 Dec 2030 (estimated)
- First posted
- 22 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the safety, tolerability, and preliminary efficacy of ZR001, a novel chemogenetic gene therapy product, in patients with moderately advanced Parkinson's disease (PD). ZR001 is administered via stereotactic injection into the bilateral substantia nigra, followed by postoperative ultra-low-dose clozapine to activate the transduced direct pathway, with the goal of improving motor symptoms of Parkinson's disease.
Detailed description
This is a first-in-human (FIH), open-label, single-arm, single-dose, dose-escalation study. The trial plans to enroll 6-8 patients with moderately advanced PD across three dose cohorts: 0.5E12, 1.0E12, and 2.0E12 vg/participant. All participants will receive a single bilateral stereotactic injection into the substantia nigra under robot-assisted guidance. To mitigate immunogenicity, prophylactic corticosteroids will be administered (intravenous methylprednisolone followed by a 12-week oral prednisone taper). Four weeks after injection, oral clozapine will be titrated over 9 days to a maintenance dose of 3.125 mg (1/8 tablet) twice daily, continued through Week 52. The study includes a 60-day screening period, an inpatient stay from Day 1 to Day 7, and outpatient follow-up visits through Week 52 at Weeks 4, 8, 12, 26, 39, and 52. After completion, participants will be invited to participate in a 5-year long-term follow-up study.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Single Group Assignment: An Open-label, Single Arm, Dose-Escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ZR001 administration.
| Arm | Type | Receives |
|---|---|---|
| ZR001 group | Experimental | Genetic: ZR001The study will enroll up to 3 cohorts: low-dose, medium-dose, and high-dose ZR001 administration. |
Who may qualify
- Ages
- 40 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Participants who meet all of the following criteria are eligible for enrollment:
Key exclusion criteria (17 listed)
- Participants who meet any of the following criteria will be excluded from this study:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ZR001This is a prospective, open-label, single-arm, single-dose, dose-escalation, investigator-initiated trial. A sentinel-based 3+ design will evaluate three dose cohorts: 0.5E12, 1.0E12, and 2.0E12 vg/participant. One sentinel participant is enrolled per cohort; a Safety Review Committee assesses safety at 6-8 weeks post-injection before escalation. After completing escalation, remaining participants are enrolled at the selected dose for expansion. Total planned enrollment is 6-8 evaluable participants. | Genetic | ZR001 group |
Primary outcome
The incidence of adverse events and serious adverse events after ZR001 treatment
Time frame: 52 weeks
Adverse events and serious adverse events will be collected from dosing through Week 52; Including vital signs, clinical laboratory parameters, and physical examinations
14 secondary outcomes
The differences of the daily levodopa equivalent dose (LED) after ZR001 treatment
Time frame: 52 weeks
The differences of the Clinical Global Impression - Severity (CGI-S) after ZR001 treatment
Time frame: 52 weeks
The differences of the Clinical Global Impression - Improvement (CGI-I) after ZR001 treatment
Time frame: 52 weeks
The differences of the MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS) after ZR001 treatment
Time frame: 52 weeks
The differences of the Parkinson's Disease Questionnaire 39 (PDQ-39) after ZR001 treatment
Time frame: 52 weeks
The differences of the Non-Motor Symptom Scale (NMSS) after ZR001 treatment
Time frame: 52 weeks
The differences of the Parkinson's Disease Sleep Scale (PDSS) after ZR001 treatment
Time frame: 52 weeks
The differences of the Pittsburgh Sleep Quality Index (PSQI) after ZR001 treatment
Time frame: 52 weeks
The differences of the Montreal Cognitive Assessment (MoCA) after ZR001 treatment
Time frame: 52 weeks
The differences of the Mini Mental State Examination (MMSE) after ZR001 treatment
Time frame: 52 weeks
The differences of the Hamilton Depression Rating Scale (HAM-D) after ZR001 treatment
Time frame: 52 weeks
The differences of the Hamilton Anxiety Scale (HAM-A) after ZR001 treatment
Time frame: 52 weeks
The differences of the viral shedding after ZR001 treatment
Time frame: 52 weeks
The humoral and cellular immune responses to ZR001
Time frame: 52 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Parkinson's Disease (PD)
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingObservational study
Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation
Parkinson Disease
Not yet recruiting
Unilateral and Staged Bilateral Pallidothalamic Tractotomy Using Exablate MRgFUS in Advanced Parkinson's Disease.
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
Jinan, China
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing ZR001 in people with Parkinson's Disease (PD) and Parkinsonian Disorders, run by Qianfoshan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The incidence of adverse events and serious adverse events after ZR001 treatment (time frame: 52 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2026.